Ketamine: Leading the New Wave of Antidepressants?

Fast-Acting Party Drug Could be in the Pipeline for Depression Treatment

Chris Lyford

Since it was introduced as an anesthetic in the 1970s, ketamine has occupied an uncertain pharmacological status. It’s been used as both a Vietnam-era battlefield painkiller and an illicit party drug, better known as Special K. But recent findings in studies around the world have some researchers wondering whether it might be the silver bullet for depression that Prozac and its sidekicks never turned out to be.

By now, the limitations of the SSRIs are widely known. Only 27 percent of depressed patients using SSRIs achieve remission of symptoms within 12 weeks, according to NIMH’s landmark STAR*D study. Even when SSRIs work, they take an average of 7 to 10 weeks to take effect. And in many cases, they have side effects too undesirable for clients to stick with them.

Some researchers now believe that ketamine could be the forerunner of a new generation of antidepressants with startling effectiveness. Administered intravenously over the course of 40 minutes, it can alleviate symptoms of depression within two hours. This has already led to ketamine’s use in cases of high suicide risk, where the stakes are high and time is often short. Even after its initial effects wear off, many clients report feeling less depressed, even days after the initial injection.

“I think ketamine’s one of the most promising drugs to come along in decades,” says John Preston, professor emeritus at Alliant International University in Sacramento and author of You Can Beat Depression: A Guide to Prevention and Recovery. “The holy grail in treating depression is finding something that works fast. If they have to wait several weeks, a lot of patients will give up, and the dropout rates for treatment are really high.”

Nevertheless, ketamine is often written off as a shady club drug. Critics say its hallucinogenic effects are a real danger, emphasizing that its side effects can include euphoric floating sensations, dizziness, confusion, an abnormal heart rate, and in extreme cases, schizophrenia-like dissociation, colloquially called “entering the K-Hole.” However, proponents argue that when ketamine is used properly under clinical supervision, these symptoms are mild and usually dissipate within an hour after injection.

A more formidable obstacle to the use of ketamine as an antidepressant is the absence of Food and Drug Administration (FDA) approval, which makes it impossible to receive insurance reimbursement for its use. As a result, individual injections can cost anywhere from $300 to $1,000.

However, recent news indicates that the tide may be changing. Last November, the FDA granted ketamine “breakthrough therapy” status to permit its study in clinical research settings, where it’s administered as an antidepressant to a select few.

Currently, there’s a lack of consensus on ketamine’s proper dosage. Most administrations involve intravenous infusions of 0.5 mg over an average of 40 minutes, but the effects of this dosage vary widely, based on factors like age, body weight, heart health, and other medications the client may be taking. “Ketamine has never really been used in the doctor’s office as an antidepressant,” says Frank Anderson, a psychiatrist and supervisor at the Trauma Center of the Justice Resource Institute, who works with patients who’ve used ketamine recreationally, sometimes consuming toxic amounts of it.

“If it’s ever going to be more widely accepted, ketamine will need to be highly regulated,” he says. “The damage is that it’ll be administered inappropriately, as with a lot of prescribers who overuse benzodiazepines and get patients hooked on them.”

Most pharmaceutical companies see little incentive to research or market the drug, as it’s already available in a generic form. “Ketamine is an old drug whose patent expired decades ago, and is very cheap to manufacture generically,” reads the Ketamine Advocacy Network website, “which means it will never produce blockbuster profits.”

However, this isn’t preventing some pharmaceutical companies from repurposing and rebranding ketamine, most notably the Illinois-based company Naurex. In December of last year, Naurex created a ketamine nasal spray, dubbing the new concoction GLYX-13. In a trial involving nearly 400 patients, about half reported reduced signs of depression, without hallucinatory side effects.

“You’d better believe that drug companies are salivating,” says Preston. “They’re figuring out ways to make using ketamine more profitable, and when they get enough information, what they’re probably going to do is develop drugs that are similar to ketamine so they can patent them.”

SSRIs like Paxil and Prozac target serotonin receptors, but ketamine targets the glutamate system, the major excitatory neurotransmitter in the brain. Proponents believe the release of glutamate enabled by ketamine results in the formation of new brain synapses and greater density of the dendritic spines on neurons that promote connectivity between them. A 2010 study at Yale University found that administering ketamine to rats led to increased growth and function in spine synapses in the prefrontal cortex, counteracting growth deficits that typically follow depressed episodes.

Only additional research and clinical trials on a broader scale will determine whether ketamine will be a game changer in depression treatment. Teams at the National Institute of Mental Health are already assessing the effects of dosing adjustments, raising dosage levels to 2 mg in later stages of treatment. Study coordinators are also looking at combining ketamine treatments with electroconvulsive therapy and other medications.

At this point, no one is saying that ketamine alone holds the key to curing depression. Time will tell whether ketamine heralds the development of a new generation of fast-acting remedies, but most therapists believe that, given the complex biopsycho-social nature of depression, a single biological intervention is unlikely to yield a revolutionary cure.

“There are always limitations to medications,” says Preston. “But right now, ketamine is the talk of the town.”

This blog is excerpted from “Is Ketamine the New Antidepressant to Rave About?". The full version is available in the May/June 2015 issue. To subscribe, click here. >>

Want to read more articles like this? Subscribe to Psychotherapy Networker Today!>>

Topic: Anxiety/Depression

Tags: antidepressants | curing depression | depression | depression treatment | drugs | mental health | prozac | psychotherapy | SSRI | ssris | therapy | drug | networker | ketamine | antidepressant | john preston | chris lyford | illegal | street drug | party

Comments - (existing users please login first)
Your email address will not be published. Required fields are marked *

*
*
*
4 Comments

Friday, October 14, 2016 11:54:38 AM | posted by Lora johnson
I am 66 years old. Have tried every antidepressant on the market, with no results. Is there any trials for ketamine in Omaha or Lincoln Nebraska? &

Saturday, May 28, 2016 8:49:52 PM | posted by Max Loudenback
I have struggled with uni-polar (Major) Depression since my 20"s, and I am 68 years old now. I would really love to give up this affliction before I pass away from old age.

Thursday, May 19, 2016 2:32:45 AM | posted by KIM
Why would anyone consider Ketamine for treatment for depression if the effects are not very long. For me that Ketamine would not be an option.

Saturday, March 26, 2016 1:25:26 AM | posted by Wow
I've seen people snort small lines of Ketamine, and it's kind of a given that they might lose consciousness for about 5 seconds. People stand behind the user to catch them to lye them on the floor or a bed. But, when the user comes to, there is often a profound, change in consciousness. A very expansive view of belonging in the world, even in normally anxious people. Drug companies still cannot fully describe how SSRI or SNRIs work, and the results can be horrible. Ketamine, DMT, MDMA, peyote, psilocybin, and even LSD can change a person's, under very controlled circumstances, view of their place in the world. But drugs like Effexor, disgusting, modality not known, FDA approved. I assume that the difference is that have had "illegal fun" with the non-approved drugs. I'm a recovering alcoholic, can't touch any of them. Just wanted to voice what I've seen.